Liposomal Bupivacaine in Bariatric Surgery

• Status: Completed
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to perform a randomized controlled trial for patients undergoing bariatric surgery, comparing the need for opiates with and without administration of a transversus abdominis plane (TAP) block using the long acting local anesthetic, liposomal bupivacaine (Exparel®). From this study, the investigators will assess whether use of long acting local anesthetic can reduce the need for opiates in the bariatric population.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Obese patients undergoing bariatric surgery (LSG or LRYGB)

• Patients 18 years of age and older

• Surgical treatment between 01/01/2018 and 12/31/2018 over a 1 year period

Exclusion Criteria:

• Patients under the age of 18 years old

• Patients taking any opiates within 30 days of enrollment in the trial

• Patients with a history of chronic pain.

• Patients taking pregabalin or gabapentin.

• ASA IV

• Prior laparotomy

• Body Mass Index ≥ 60 kg/m2

• History of cardiac arrhythmia

• History of Seizure

• Psychiatric Diagnosis currently on antipsychotic medication